A Phase II Study of Local Ablative Therapy in People with Metastatic Non-Small Cell Lung Cancer and a High Risk of Cancer Progression


Full Title

A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) using Minimal Residual Disease (MRD) as an Integral Biomarker


The purpose of this study is to assess the use of local ablative therapy (LAT) in people with metastatic non-small cell lung cancer (NSCLC) and minimal residual disease (MRD). MRD is when a very small number of cancer cells can be detected in the blood, which indicates the patient’s cancer as a high chance of getting worse.

In this study, patients will receive LAT when their MRD levels are rising. LAT is treatment that focuses on and destroys tumors in a certain area of the body (rather than throughout the entire body, like systemic therapy). LAT can include radiation therapy, surgery, and/or radiofrequency ablation (using a needle-like probe and high-energy radio waves to destroy cancer cells). It is hoped that LAT is useful during the earliest “pre-progression” stage of cancer in the blood, can reduce MRD levels, and can control metastatic NSCLC longer than systemic therapy (such as chemotherapy and immunotherapy).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have metastatic NSCLC and have received prior treatment, but still have some tumors remaining to be targeted with LAT.
  • Patients must have MRD.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr.  Daniel Gomez at 212-639-2087.




Phase II (phase 2)